Biologic Therapy

SAN DIEGO — Patients with severe asthma experienced fewer exacerbations with 6 months of treatments with biologics, according to a study presented at the American Thoracic Society International Conference.

Bimekizumab treatment for psoriatic arthritis demonstrated rapid, clinically meaningful improvements to patient reported outcomes that were sustained up to 1 year, according to data published in Rheumatology.

SAN DIEGO — Asthma remission may occur more often with the use of biologics, but non-white patients receive fewer biologics than white patients, according to an abstract presented at the American Thoracic Society International Conference.

Published results showed osteochondral allograft transplantation, autologous chondrocyte implantation and matrix-induced autologous chondrocyte implantation all yielded similar outcomes for patients with patellofemoral cartilage defects.

Early use of biologics like belimumab may limit complications associated with steroid use and improve long-term outcomes in systemic lupus erythematosus, according to data presented at the EULAR 2024 Congress.

SAN DIEGO — After 1 year of biologic therapy, patients with COPD and Th2 inflammation experienced fewer exacerbations and hospitalizations, according to research presented at the American Thoracic Society International Conference.

Physician understanding about the safety and efficacy of Janus kinase inhibitors for patients with rheumatoid arthritis has evolved with real-world and clinical trial data.

The FDA has granted orphan drug designation to a microbiome-modifying biologic to treat Angelman syndrome, according to the manufacturer.

DESTIN, Fla. — New data on discontinuation or dose reduction of biologic therapies has led to a shifting landscape in axial spondyloarthritis management, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.